What is Gintop Lafrancol?
Gintop Lafrancol belongs to a group of medicines called antiprotozoals. It is used to treat diarrhea that is caused by certain types of protozoa (tiny, one-celled animals).
Gintop Lafrancol is available only with your healthcare professional's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Gintop Lafrancol is used in certain patients with the following medical condition:
- Intestinal parasitic infections
Gintop Lafrancol indications
Diarrhea Caused by Giardia Lamblia or Cryptosporidium Parvum
Gintop Lafrancol for
Oral Suspension (patients 1 year of age and older) and Gintop Lafrancol Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Limitations Of Use
Gintop Lafrancol for
Oral Suspension and Gintop Lafrancol Tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients.
How should I use Gintop Lafrancol?
Use Gintop Lafrancol suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Gintop Lafrancol suspension with food.
- Shake well before using.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you miss a dose of Gintop Lafrancol suspension, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Gintop Lafrancol suspension.
Uses of Gintop Lafrancol in details
Use: Labeled Indications
Diarrhea, infectious: Treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia
Off Label Uses
Clostridioides (formerly Clostridium) difficile infection
Current evidence from small, controlled trials regarding the use of Gintop Lafrancol in the management of C. difficile infection suggests that it may be comparable to the use of oral metronidazole or vancomycin. The Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology (SHEA) clinical practice guidelines for C. difficile infection state that Gintop Lafrancol is considered a probable effective alternative for primary C. difficile infection in adults without specific recommendations for use. Larger controlled trials are needed.
Cryptosporidiosis-associated diarrhea in HIV-infected patients
Based on the US Department of Health and Human Services (HHS) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, Gintop Lafrancol may be considered as an alternative agent in the management of diarrhea caused by Cryptosporidium in HIV-infected patients (must be used in combination with optimized antiretroviral therapy (ART), electrolyte replacement, and symptomatic treatment and rehydration).
Gintop Lafrancol description
Gintop Lafrancol, also known by the brand name Gintop Lafrancol, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1–4 hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea. [Wikipedia]
Gintop Lafrancol dosage
Gintop Lafrancol Dosage
Generic name: Gintop Lafrancol 500mg
Dosage form: tablet; powder, for oral suspension
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
2.1 Recommended Dosage and Important Administration Instructions
Important Administration Instructions for Pediatric Patients 11 years of Age or Younger:
Gintop Lafrancol tablets should not be administered to pediatric patients 11 years of age or younger because a single tablet contains a greater amount of Gintop Lafrancol than the recommended dosing in this pediatric age group.
Table 1. Recommended Dosage
| Age | Dosage | Duration |
| 1-3 years | 5 mL of Gintop Lafrancol for Oral suspension(100 mg Gintop Lafrancol) taken orally every 12 hours with food | |
| 4-11 years | 10 mL of Gintop Lafrancol for Oral Suspension(200 mg Gintop Lafrancol) taken orally every 12 hours with food | 3 Days |
| 12 years and older | One Gintop Lafrancol Tablet (500 mg Gintop Lafrancol) taken orally every 12 hours with food or 25 mL of Gintop Lafrancol for Oral Suspension (500 mg Gintop Lafrancol) taken orally every 12 hours with food |
2.2 Directions for Mixing Gintop Lafrancol for
Oral Suspension
Reconstitute Gintop Lafrancol for
Oral Suspension as follows:
- Measure 48 mL of water for preparation of the 100 mg/5 mL suspension
- Tap bottle until all powder flows freely.
- Add approximately one-half of the 48 mL of water required for reconstitution and shake vigorously to suspend powder.
- Add remainder of water and again shake vigorously
Keep container tightly closed, and shake the suspension well before each administration. The reconstituted suspension may be stored for 7 days at room temperature, after which any unused portion must be discarded.
More about Gintop Lafrancol (Gintop Lafrancol)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Gintop Lafrancol
- Gintop Lafrancol suspension
- Gintop Lafrancol (Advanced Reading)
Professional resources
- Gintop Lafrancol (AHFS Monograph)
- Gintop Lafrancol (FDA)
Related treatment guides
- Ascariasis
- Giardiasis
- Dwarf Tapeworm Infection (Hymenolepis nana)
- Amebiasis
- Cryptosporidiosis
Gintop Lafrancol interactions
See also:
What other drugs will affect Gintop Lafrancol?
Tizoxanide is highly bound to plasma protein (>99.9%). Therefore, caution should be used when administering Gintop Lafrancol concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when Gintop Lafrancol is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.
Gintop Lafrancol side effects
See also:
What are the possible side effects of Gintop Lafrancol?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of Gintop Lafrancol was evaluated in 2177 HIV-uninfected subjects 12 months of age and older who received Gintop Lafrancol Tablets or Gintop Lafrancol for
Oral Suspension at the recommended dose for at least three days. In pooled controlled clinical trials involving 536 HIV-uninfected subjects treated with Gintop Lafrancol Tablets or Gintop Lafrancol for
Oral Suspension, the most common adverse reactions were abdominal pain, headache, chromaturia and nausea ( > 2%).
Safety data were analyzed separately for 280 HIV-uninfected subjects ≥ 12 years of age receiving Gintop Lafrancol at the recommended dose for at least three days in 5 placebo-controlled clinical trials and for 256 HIV-uninfected subjects 1 through 11 years of age in 7 controlled clinical trials. There were no differences between the adverse reactions reported for Gintop Lafrancol-treated subjects based upon age.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of Gintop Lafrancol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following is a list of adverse reactions spontaneously reported with Gintop Lafrancol Tablets which were not included in clinical trial listings:
Gastrointestinal disorders: diarrhea, gastroesophageal reflux disease
Nervous System disorders: dizziness
Respiratory, thoracic and mediastinal disorders: dyspnea
Skin and subcutaneous tissue disorders: rash, urticaria
Gintop Lafrancol contraindications
See also:
What is the most important information I should know about Gintop Lafrancol?
Hypersensitivity
Gintop Lafrancol Tablets and Gintop Lafrancol for
Oral Suspension are contraindicated in patients with a prior hypersensitivity to Gintop Lafrancol or any other ingredient in the formulations.
Active ingredient matches for Gintop Lafrancol:
Nitazoxanide in Ecuador.
List of Gintop Lafrancol substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Gintop (Ecuador) | |
| Givotan (Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama) | |
| Jointax (Colombia) | |
| Kaside (Peru) | |
| Kazide (Colombia) | |
| Kidonax (Mexico) | |
| Suspension; Oral; Nitazoxanide 100 mg / 5 ml (Unipharm) | |
| Tablet, Dispersible; Oral; Nitazoxanide 200 mg (Unipharm) | |
| Tablet; Oral; Nitazoxanide 500 mg (Unipharm) | |
| Larvisol (Colombia) | |
| Lumbris (Peru) | |
| Mitafar (Mexico) | |
| Mixel (Colombia) | |
| N-TEE (India) | |
| N-TEE dry syr 100 mg x 5 mL x 30ml (Olcare) | $ 0.43 |
| Nanazoxid (Egypt) | |
| Navigator (United States) | |
| Netazox (India) | |
| Netazox 200mg DT- TAB / 60 (Ind-Swift Limited) | $ 3.99 |
| Netazox 500mg FC- TAB / 60 (Ind-Swift Limited) | $ 5.57 |
| Netazox 100mg/5mL SUSP / 30ml (Ind-Swift Limited) | $ 0.30 |
| 100 mg x 5 mL x 30ml (Ind-Swift Limited) | $ 0.30 |
| 200 mg x 60's (Ind-Swift Limited) | $ 3.99 |
| 500 mg x 60's (Ind-Swift Limited) | $ 5.57 |
| Netazox 30 ml Suspension (Ind-Swift Limited) | $ 0.05 |
| NETAZOX 100MG SUSPENSION 1 bottle / 30 ML suspension each (Ind-Swift Limited) | $ 0.49 |
| NETAZOX 200MG TABLET 1 strip / 6 tablets each (Ind-Swift Limited) | $ 0.65 |
| NETAZOX 500MG TABLET 1 strip / 6 tablets each (Ind-Swift Limited) | $ 0.91 |
| NETAZOX DT 200 MG TABLET 1 strip / 10 tablets each (Ind-Swift Limited) | $ 0.59 |
| NETAZOX dry syr 100 mg x 5 mL x 30ml (Ind-Swift Limited) | $ 0.30 |
| NETAZOX dispertab 200 mg x 6's (Ind-Swift Limited) | $ 0.40 |
| NETAZOX film-coated tab 500 mg x 6's (Ind-Swift Limited) | $ 0.56 |
| Netazox 100mg/5ml Suspension (Ind-Swift Limited) | $ 0.49 |
| Netazox 200mg Tablet (Ind-Swift Limited) | $ 0.12 |
| Netazox 200mg Tablet DT (Ind-Swift Limited) | $ 0.06 |
| Netazox 500mg Tablet (Ind-Swift Limited) | $ 0.17 |
| Netazox -OF | |
| Netazox -OF Nitazoxanide 100mg, Ofloxacin50mg/5mL SUSP / 50ml | $ 0.72 |
| Netazox -OF Nitazoxanide 500mg, Ofloxacin200mg TAB / 60 | $ 7.19 |
| Netazox DT | |
| Netazox DT 200 mg Tablet (Ind-Swift Limited) | $ 0.06 |
| Netazox FC | |
| Netazox FC 500 mg Tablet (Ind-Swift Limited) | $ 0.09 |
| Niazid (Bangladesh) | |
| Nicud (Bangladesh) | |
| Nidozox (Bangladesh) | |
| Nit Clean (Egypt) | |
| Nitacol | |
| Nitacol 30 ml Suspension (Rexcel Pharmaceuticals Ltd) | $ 0.04 |
See 375 substitutes for Gintop Lafrancol | |
References
- DailyMed. "NITAZOXANIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "NITAZOXANIDE". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "NITAZOXANIDE". http://www.drugbank.ca/drugs/DB00507 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Gintop Lafrancol are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Gintop Lafrancol. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Gintop Lafrancol drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 1 | 100.0% | |
Consumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Gintop Lafrancol before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Gintop Lafrancol. To get the time effectiveness of using Gintop Lafrancol drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 day | 1 | 100.0% | |
Consumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
